Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. - Wikidata - awgldk - TriplyDB

Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

http://www.wikidata.org/entity/Q36747438

about

Assessing antiangiogenic therapy response by DCE-MRI: development of a physiology driven multi-compartment model using population pharmacometrics Commentary on Dartois et al.--model building in population PK-PD analyses. A 2002-2004 literature survey Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.Evaluation of different tests based on observations for external model evaluation of population analyses.Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.Predictive performance of a gentamicin population pharmacokinetic model in neonates receiving full-body hypothermia Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates A hemodynamic model to guide blood pressure control during deliberate hypotension with sodium nitroprusside in children.Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients.Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration Modeling the pharmacokinetic-pharmacodynamic relationship of the monoclonal anti-macaque-IL-15 antibody Hu714MuXHu in cynomolgus monkeys.Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation.Cross-validation for nonlinear mixed effects models Population pharmacokinetics of abacavir in infants, toddlers and children.Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants The role of population PK-PD modelling in paediatric clinical research.Understanding the time course of pharmacological effect: a PKPD approach.The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.Limited-sampling strategies for anti-infective agents: systematic review.Fundamentals of population pharmacokinetic modelling: validation methods.Population pharmacokinetic analysis during the first 2 years of life: an overview.Population pharmacometrics in support of analgesics studies.Development of a complex parent-metabolite joint population pharmacokinetic model.How to use vancomycin optimally in neonates: remaining questions.Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates.Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns.Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B.Characterizing the dynamic interaction among gastric emptying, glucose absorption, and glycemic control in nondiabetic obese adults.Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis.Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.External Validation of a Recently Developed Population Pharmacokinetic Model for Hydromorphone During Postoperative Pain Therapy.Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.MatVPC: A User-Friendly MATLAB-Based Tool for the Simulation and Evaluation of Systems Pharmacology Models.A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates.Pharmacokinetics of dexmedetomidine combined with therapeutic hypothermia in a piglet asphyxia model.

P2860

Q27316303-E87CF12E-244C-4E9D-978D-198B2205C21B Q28755933-16D9E01A-A000-45BF-B360-0A0944517571 Q33824750-32A29206-F09F-4B4E-9676-4340C309645F Q33869167-C18642D6-8836-417E-A8BA-2BB86987CA7E Q34026240-591690E4-C0DA-4505-990E-CE39E26D90E9 Q34200271-7DD70307-2E9D-4B7E-9ECC-CE4B9767651E Q35752756-79ACA997-261A-4F9E-9A32-22BF963B27A6 Q35894569-2B42F49D-831F-4619-B762-15AF86B16B75 Q35960694-CEAC0D5C-AEFE-4229-A0EB-0E6DAC45780D Q36110601-26030036-31C9-4044-94B2-669CE43973AA Q36112215-FE38BAB1-FF9D-4161-9FC0-A4368694836B Q36125427-384C7984-4118-4559-A052-57D87B727DBC Q36388088-28EB6E69-894C-452C-B711-DEEAA3C1331B Q36568925-7B5D8DAE-74E2-4704-8F6A-E5F4086A9C1C Q36648845-DB709025-99C7-46AA-8643-29F4451B4DB3 Q36881201-F10F4880-7F2C-4A4C-B36B-8C63294255D2 Q36891147-DCF8DBDE-DC36-4424-84AB-8339AED1537B Q36948138-E3721370-C30A-4052-8701-8ED08A353171 Q37120041-C8A8624B-8A91-4295-B5F6-66B1A684D3E0 Q37719346-B36136F5-50DE-4601-AFE8-23FDCCE99DE4 Q37832754-86F9365B-B857-4F02-92A4-49E6150BE7DB Q37996075-1D4B82B2-4C8F-4F47-917A-2BEF423A729D Q38000241-423999BC-AC48-40FD-A723-A537CD622DCA Q38026590-7E3CEF2C-80CB-4E1B-9215-9EC7795D526D Q38062388-BB54005B-53EA-4F9C-A562-CD2FFAA86EF5 Q38175171-252AC692-6A5F-42DD-B1B7-02A898D272A3 Q38254581-31CA4D5D-8FF9-41AF-B391-93297F55A1CD Q38569678-20294D17-8F55-44D4-B797-3744F871467D Q38696468-5573D4CA-5B79-4ECA-BF06-4F10A268CCAA Q38850670-372036D5-F2D0-4169-BC4D-BAF39EE5E1EC Q38865904-C0EF9874-3B26-400E-8B85-BFD897C785FA Q38935228-9E50E65D-1710-4907-B86A-D7AFF8A8E9C0 Q39100650-7AD99081-AC3F-4EBC-9BDB-8D2C58925CC0 Q39234438-7B8D3645-5ED3-44C1-AD27-036EB65FA253 Q39937143-65EB3EEF-EBE9-4822-92A0-24C7990C67E7 Q40075482-703B1F25-68A7-456A-B053-4B7E03338057 Q41079423-24FA6C35-28E5-4E24-945C-4601CD198CE5 Q41425923-1D354871-A587-496B-BBE7-C20433955450 Q41477321-16042E3E-3722-4C49-9F87-9F26E0A0EAE2 Q42910260-8C8B5BE7-3E2B-49C7-B7A4-8E3E06C54B69

P2860

Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

http://www.wikidata.org/entity/Q36747438

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Are population pharmacokinetic ...... literature from 2002 to 2004.

@en

type

label

Are population pharmacokinetic ...... literature from 2002 to 2004.

@en

prefLabel

Are population pharmacokinetic ...... literature from 2002 to 2004.

@en

P1433

Q36747438-DB009DAC-89CE-413A-BF6E-DDD8FC449191

P1476

Q36747438-66EF68E7-3C70-4375-A3F5-6FC8A7F8FA1E

P2093

Q36747438-05027E59-89AC-4B66-BB1F-CB9D5C6B63F8

Q36747438-1C2A6BCA-38A4-439D-AF94-3C9276AE3D01

Q36747438-20BBE02B-5C71-4B82-9C94-010AF016B597

Q36747438-272272C8-D8F5-4F27-B342-327E3C60FBCF

Q36747438-47F410B6-B30E-4415-9F28-4DB004CC5350

Q36747438-53EABF87-9988-4B96-A2E5-6F335A5A692A

Q36747438-9B17D728-A8B2-4937-87CA-80FA8731F8FA

Q36747438-EDFC3668-B119-4542-B2E2-2CFEB91D699D

Q36747438-FABDE650-7788-4731-BF7A-E934438D8428

P2860

Q36747438-0327D0AE-E80E-44D4-8A0B-B72D1CE9F934

Q36747438-0723F808-F502-41B9-9FAF-5C29E793E76C

Q36747438-0ED54327-3148-45EB-A02A-E585321F93BD

Q36747438-1B64AF3C-D494-4CFC-AF49-DE8B5E8B07CE

Q36747438-1E1E261C-F29B-4C97-BF7E-58D9901EDBA7

Q36747438-29B241BF-1B6F-4F95-BE1A-BB92B6321E6B

Q36747438-3153C1AD-047A-4C9D-A167-583A61BBFB5B

Q36747438-319EA3C1-5D2F-43BA-A754-9DD04573D57B

Q36747438-3B76772C-BDCE-43A5-88B1-CB16D806D86C

Q36747438-4081F90F-C209-420A-A385-20F6058C3A42

P2888

Q36747438-5BA06234-8649-45CB-B365-B3238F45FF7F

P304

Q36747438-8143E8A7-6F9E-4500-A604-517A6194CA21

P31

Q36747438-A9A9507F-24E7-4493-83BC-A7CDA45269B7

P356

Q36747438-D771A465-CEC9-48A5-A411-D6DC1F1A6E98

P433

Q36747438-4F384E0E-FE00-4638-B2FB-0C92569FF2B9

P478

Q36747438-90B1E131-821C-486B-A49C-3ED9C6247A4D

P577

Q36747438-340B6A10-E662-43FE-8D76-6BA6857F24AF

P5875

Q36747438-6D76788D-4907-462E-863A-6B4468A6D29F

P6179

Q36747438-73B071B3-FF54-499B-BD00-B14501388D17

P698

Q36747438-9800EC05-AC96-4F77-A885-22DB93838C6D

P932

Q36747438-C8C1FEAB-64F4-4877-8EE2-F45DC325B0DA

P356

00003088-200746030-00003

P1433

Clinical Pharmacokinetics

P1476

Are population pharmacokinetic ...... literature from 2002 to 2004.

@en

P2093

Annabelle Lemenuel-Diot

http://www.w3.org/2001/XMLSchema#string

Brigitte Tranchand

http://www.w3.org/2001/XMLSchema#string

Christian Laveille

http://www.w3.org/2001/XMLSchema#string

Céline Dartois

http://www.w3.org/2001/XMLSchema#string

Céline M Laffont

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Comets

http://www.w3.org/2001/XMLSchema#string

France Mentré

http://www.w3.org/2001/XMLSchema#string

Karl Brendel

http://www.w3.org/2001/XMLSchema#string

Pascal Girard

http://www.w3.org/2001/XMLSchema#string

P2860

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients

Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.

Analysis of population pharmacokinetic data using NONMEM and WinBUGS.

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

Pharmacokinetic/pharmacodynamic modeling in drug development.

Simulation of clinical trials.

Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.

Role of modelling and simulation in Phase I drug development.

Population pharmacokinetics of linezolid in patients treated in a compassionate-use program.

Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery

P2888

00003088-200746030-00003

P304

221-234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/00003088-200746030-00003

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6477175

http://www.w3.org/2001/XMLSchema#string

P6179

1046117292

http://www.w3.org/2001/XMLSchema#string

P698

17328581

http://www.w3.org/2001/XMLSchema#string

P932

2907410

http://www.w3.org/2001/XMLSchema#string